الفهرس | Only 14 pages are availabe for public view |
Abstract In recent years, Prostate cancer (PC) has risen to prominence as a public health issue affecting males. Prostate cancer is the second most commonly diagnosed cancer type in the world, and it is also among the most common causes of cancer-related death in men in both developed and developing countries (1, 2). In 2020, it accounted for 1,414,259 new cases and 375, 304 deaths, accounting for 6.8% of all cancer-related deaths in males. Men aged 65 and older account for about 60% of all prostate cancer diagnoses. Men are, on average, 66 years old when they are diagnosed with prostate cancer (3, 4). In Egypt, According to the Global Cancer Observatory (GLOBOCAN) (2020) age-standardized incidence rate is (13.9) per 100,000 and the estimated prevalent cases and deaths for all ages are (10,532) cases and (2227) deaths respectively. In Egypt, by 2040 the estimated number of incident cases and deaths of prostate cancer will expected to rise to (9607) cases and (4978) deaths, respectively. Also, the worldwide prostate cancer burden is expected to grow to almost (2,426, 825) million new cases and (739, 861) deaths by 2040 simply due to the growth and aging of the population (4, 5). |